Timothy F. Cloughesy, MD, director of UCLA’s Neuro-Oncology Program, a distinguished professor in neurology, discusses the impact and significance of the FDA’s approval of vorasidenib (Voranigo, formerly AG-881), a first-in-class option for the treatment of patients with IDH-mutant gliomas.

Vorasidenib is an oral, selective, highly brain-penetrant dual inhibitor of mutant IDH1 and IDH2 enzymes. This approval is for the treatment of patients 12 and older with IDH-mutant, grade 2 astrocytoma or oligodendroglioma.

Findings from phase 3 INDIGO trial (NCT04164901) support this approval. Here, vorasidenib significantly improved progression-free survival and delayed the time to the next intervention compared with placebo.

View the full interview with Cloughesy: [ Ссылка ]

For more resources and information regarding anticancer targeted therapies: [ Ссылка ]

свернуть